SCHEMBL19006915

SCHEMBL19006915

Cn1cnc2c1c(=O)n(Cc1ccc(Cc3ccccc3)c(Cc3ccccc3)c1)c(=O)n2Cc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.47
KMT2A Q03164 5/20 0.45
MEN1 O00255 3/20 0.45
CSF1R P07333 1/20 0.41
PDE4A P27815 2/20 0.40
ADORA2A P29274 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
ADORA2B P29275 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19006914 0.92 MAPK1 (0.53) MAPK1KMT2AMEN1CSF1RPDE4A
SCHEMBL15869890 0.82 MAPK1 (0.50) MAPK1KMT2AMEN1PDE4AADORA2A
SCHEMBL14907967 0.78 PDE4A (0.55) MAPK1KMT2AMEN1PDE4AADORA2A
SCHEMBL19006847 0.77 PDE1A (0.60) MAPK1KMT2AMEN1ADORA2BLMNA
SCHEMBL15869891 0.73 PDE1A (0.54) MAPK1KMT2AMEN1ADORA2BLMNA
SCHEMBL15869889 0.73 HIF1A (0.56) MAPK1KMT2AMEN1ADORA2BLMNA
SCHEMBL14907925 0.70 MAPK1 (0.55) MAPK1KMT2AMEN1PDE4AADORA2A
SCHEMBL23974590 0.70 ADORA2A (0.63) MAPK1PDE4AADORA2APDE4BPDE4C
SCHEMBL10394509 0.70 MAPK1 (0.73) MAPK1KMT2AMEN1ADORA2BBLM
SCHEMBL6662150 0.70 KMT2A (0.45) MAPK1KMT2AMEN1CSF1RPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2753333-B1 CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTAMED INC (US) 2017-06-21 EP disclosed